Amgen Inc. $AMGN Position Boosted by PYA Waltman Capital LLC

PYA Waltman Capital LLC lifted its position in Amgen Inc. (NASDAQ:AMGN) by 22.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,721 shares of the medical research company’s stock after buying an additional 2,530 shares during the period. Amgen makes up 1.2% of PYA Waltman Capital LLC’s holdings, making the stock its 18th largest position. PYA Waltman Capital LLC’s holdings in Amgen were worth $4,491,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares in the last quarter. State Street Corp raised its stake in shares of Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after buying an additional 1,287,310 shares in the last quarter. Capital World Investors raised its stake in shares of Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares in the last quarter. Capital International Investors raised its stake in shares of Amgen by 1.5% in the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after buying an additional 282,219 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after buying an additional 1,035,779 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen said its phase 3 ABP 938 eye-disease study is advancing, with the drug aimed at challenging Regeneron’s Eylea HD in a major retina market. That keeps Amgen’s pipeline in focus as a potential future growth driver. Article Title
• Positive Sentiment: Amgen also highlighted its MARITIME-SWITCH phase 3 obesity trial, which is designed to capture GLP-1 switchers. Any success in obesity treatment could open another large market and improve long-term revenue expectations. Article Title
• Positive Sentiment: Some coverage pointed to Amgen as a value stock with supportive new data from the VESALIUS-CV cardiovascular study for Repatha, reinforcing confidence in the company’s broader portfolio. Article Title
• Neutral Sentiment: Amgen and outside analysts published bullish commentary on the stock’s valuation and earnings profile, but these were mostly opinion pieces rather than new business developments. Article Title
• Negative Sentiment: Investor sentiment is being pressured by reports that Amgen’s Tavneos faces a proposed FDA withdrawal, with the company seeking a hearing and commissioning an independent review to defend the drug’s data. Regulatory uncertainty around a $500 million product is a meaningful risk for the stock. Article Title
• Negative Sentiment: Reuters also reported that Amgen hired a research firm to reassess Tavneos data after FDA concerns, underscoring the regulatory overhang and near-term uncertainty for the drug. Article Title

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AMGN. Guggenheim dropped their price objective on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research note on Monday, May 4th. Barclays began coverage on Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective on the stock. Piper Sandler reissued an “overweight” rating on shares of Amgen in a research note on Friday. UBS Group boosted their price objective on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Finally, Rothschild & Co Redburn raised their price objective on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research note on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $354.12.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is owned by insiders.

Amgen Stock Performance

AMGN opened at $355.20 on Monday. The firm has a market cap of $191.70 billion, a PE ratio of 24.72, a P/E/G ratio of 3.56 and a beta of 0.42. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The business has a fifty day simple moving average of $340.97 and a 200-day simple moving average of $345.80. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts predict that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.